Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16
Ramucirumab联合FOLFIRI方案作为既往接受过抗EGFR抗体治疗的RAS野生型转移性结直肠癌患者的二线治疗:JACCRO CC-16
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2023.101636
Yasui, H; Okita, Y; Nakamura, M; Sagawa, T; Watanabe, T; Kataoka, K; Manaka, D; Shiraishi, K; Akazawa, N; Okuno, T; Shimura, T; Shiozawa, M; Sunakawa, Y; Ota, H; Kotaka, M; Okuyama, H; Takeuchi, M; Ichikawa, W; Fujii, M; Tsuji, A